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Cofactor F420 plays critical roles in primary and secondary metabolism in a range of bacteria
and archaea as a low-potential hydride transfer agent. It mediates a variety of important
redox transformations involved in bacterial persistence, antibiotic biosynthesis, pro-drug
activation and methanogenesis. However, the biosynthetic pathway for F420 has not been
fully elucidated: neither the enzyme that generates the putative intermediate 2-phospho-L-
lactate, nor the function of the FMN-binding C-terminal domain of the γ-glutamyl ligase
(FbiB) in bacteria are known. Here we present the structure of the guanylyltransferase FbiD
and show that, along with its archaeal homolog CofC, it accepts phosphoenolpyruvate, rather
than 2-phospho-L-lactate, as the substrate, leading to the formation of the previously
uncharacterized intermediate dehydro-F420-0. The C-terminal domain of FbiB then utilizes
FMNH2 to reduce dehydro-F420-0, which produces mature F420 species when combined with
the γ-glutamyl ligase activity of the N-terminal domain. These new insights have allowed the
heterologous production of F420 from a recombinant F420 biosynthetic pathway in Escherichia
coli.
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Cofactor F420 is a deazaﬂavin that acts as a hydride carrier indiverse redox reactions in both bacteria and archaea1,2.While F420 structurally resembles the ﬂavins ﬂavin
mononucleotide (FMN) and ﬂavin adenine dinucleotide (FAD), it
functions as an obligate two-electron hydride carrier and
hence is functionally analogous to the nicotinamides NAD+ and
NADP+ 3. The lower reduction potential of the F420, relative to
the ﬂavins, results from the substitution of N5 of the isoalloxazine
ring in the ﬂavins for a carbon in F4204,5. Originally characterized
from methanogenic archaea in 19724,5, F420 is an important
catabolic cofactor in methanogens and mediates key one-carbon
transformations of methanogenesis6. F420 has since been shown
to be synthesized in a range of archaea and bacteria1,2,7,8.
In Mycobacterium tuberculosis, the causative agent of tubercu-
losis, F420 has been shown to contribute to persistence9,10 and to
activate the new clinical antitubercular prodrugs delamanid and
pretomanid11. There are also growing numbers of natural pro-
ducts that have been shown to be synthesized through F420-
dependent pathways, including tetracyclines12, lincosamides13,
and thiopeptides14. F420-dependent enzymes have also been
explored for bioremediation and biocatalytic applications15,16.
The currently accepted F420 biosynthetic pathway consists of
two branches2 (Fig. 1). In the ﬁrst branch, tyrosine is condensed
with 5-amino-6-ribitylamino-2,4[1H,3H]-pyrimidinedione from
the ﬂavin biosynthetic pathway to generate the deazaﬂavin chro-
mophore Fo (7,8-didemethyl-8-hydroxy-5-deazariboﬂavin) via the
activity of the two-domain Fo synthase FbiC, or the CofG/H pair
(where “Fbi” refers to mycobacterial proteins and “Cof” refers to
archaeal homologs). In the second branch, it has been hypothe-
sized that a 2-phospho-L-lactate guanylyltransferase (CofC in
archaea and the putative enzyme FbiD in bacteria) catalyzes the
guanylylation of 2-phospho-L-lactate (2-PL) using guanosine-5ʹ-
triphosphate (GTP), yielding L-lactyl-2-diphospho-5ʹ-guanosine
(LPPG)17. The two branches then merge at the reaction catalyzed
by the transferase FbiA/CofD, where the 2-phospho-L-lactyl
moiety of LPPG is transferred to Fo, forming F420-018,19. Finally,
the γ-glutamyl ligase (FbiB/CofE) catalyzes the poly-glutamylation
of F420 to generate mature F420, with poly-γ-glutamate tail lengths
of ~2–8, depending on species20,21.
There are three aspects of the F420 biosynthetic pathway that
require clariﬁcation. First, the metabolic origin of 2-PL, the
proposed substrate for CofC, is unclear. It has been assumed that
a hypothetical kinase (designated CofB) phosphorylates L-lactate
to produce 2-PL22. However, no such enzyme has been identiﬁed
in bacteria or archaea, and our genomic analysis of F420 bio-
synthesis operons has failed to identify any candidate enzymes
with putative L-lactate kinase activity2. Second, the existence of
FbiD has only been inferred through bioinformatics and genetic
knockout studies and the enzyme has not been formally char-
acterized23,24. Finally, the bacterial γ-glutamyl ligase FbiB is a
two-domain protein20, in which the N-terminal domain is
homologous to other F420-γ-glutamyl ligases (including the
archaeal equivalent, CofE) and the C-terminal domain adopts an
FMN-binding nitroreductase (NTR) fold20. Although both
domains are required for full γ-glutamyl ligase activity, no
function has been associated with either the C-terminal domain
or the FMN cofactor, given no redox reactions are known to be
involved in F420 biosynthesis.
Here we demonstrate that 2-PL is not required for F420 bio-
synthesis in prokaryotes and instead phosphoenolpyruvate (PEP),
an abundant intermediate of glycolysis and gluconeogenesis, is
incorporated into F420. Mass spectrometry (MS) and protein
crystallography are used to demonstrate that PEP guanylylation is
catalyzed by the FbiD/CofC enzymes that were previously
thought to act upon 2-PL. In bacteria, the incorporation of PEP in
the pathway results in the production of the previously
undetected intermediate dehydro-F420-0, which we identiﬁed by
MS. We then showed, with the help of ligand docking, that this
intermediate is then reduced by the C-terminal domian and poly-
glutamylated by the N-terminal domain. These ﬁndings result in
a substantially revised pathway for F420 biosynthesis and have
allowed us to heterologously express a functional F420 biosyn-
thetic pathway in Escherichia coli, an organism that does not
normally produce F420, at levels comparable to some native F420-
producing organisms.
Results
FbiD/CofC accept PEP, rather than 2-PL. The archaeal enzyme
CofC has previously been suggested to catalyze the guanylylation
of 2-PL to produce LPPG during F420 biosynthesis (Fig. 2a)25.
Another study, using transposon mutagenesis, has shown that
MSMEG_2392 of Mycobacterium smegmatis is essential in the
biosynthesis of F420 from Fo23. We have recently shown that
homologs of this gene have sequence homology to CofC and
belong to operons with other validated F420 biosynthetic genes in
a wide variety of bacteria2. In keeping with the bacterial naming
system, we refer to this enzyme as FbiD. To test the function of
this putative bacterial FbiD, we cloned the homologous Rv2983
gene from M. tuberculosis26 into a mycobacterial expression
vector and puriﬁed heterologously expressed Mycobacterium
tuberculosis FbiD (Mtb-FbiD) from M. smegmatis mc24517 host
cells. We also expressed and puriﬁed Mtb-FbiA (the enzyme
thought to transfer the 2-phospho-L-lactyl moiety of LPPG to Fo
to produce F420-0)18 to use in coupled high-performance liquid
chromatography-MS (HPLC-MS) enzymatic assays with Mtb-
FbiD. Surprisingly, we found that when Mtb-FbiD and Mtb-FbiA
were included in an assay with 2-PL, GTP (or ATP), and Fo, no
product was formed (Fig. 2b). We then tested whether Mtb-FbiA
and CofC from Methanocaldococcus jannaschii (Mj-CofC) could
catalyze F420-0 formation under the same conditions, which again
yielded no product (Fig. 2b).
Although 2-PL is hypothesized to be an intermediate in F420
biosynthesis, this has never been experimentally conﬁrmed in
bacteria. Additionally, no enzyme capable of phosphorylating
L-lactate to 2-PL has been identiﬁed in F420-producing organisms,
despite considerable investigation22. 2-PL has been little studied
as a metabolite and is only known to occur as a by-product of
pyruvate kinase activity27. 2-PL has not been implicated as a
substrate in any metabolic pathway outside the proposed role in
F420 biosynthesis; rather, it has been shown in vitro to inhibit
several enzymes involved in glycolysis and amino acid biosynth-
esis28–30. Our inability to detect activity with 2-PL led us to
consider alternative metabolites that could potentially substitute
for 2-PL, including the structurally analogous and comparatively
abundant molecule PEP31 (Fig. 2a).
While there was no activity when 2-PL was used in the FbiD/
CofC:FbiA-coupled assays, when these enzymes were incubated
with PEP, GTP (or ATP), and Fo, a previously unreported
intermediate in the F420 biosynthesis pathway, which we term
“dehydro-F420-0,” was produced (Fig. 2b). The identity of this
compound, which is identical to F420-0 except for a methylene
group in place of the terminal methyl group, was veriﬁed by MS/
MS (Fig. 2c). The only difference that we observed between the
activities of Mtb-FbiD and Mj-CofC was that while Mtb-FbiD
exclusively utilizes GTP to produce dehydro-F420-0, Mj-CofC can
also catalyze the reaction with ATP, albeit to a lesser extent
(Fig. 2b). Interestingly, in our experiments the FbiD/CofC
enzymes were only active in the presence of FbiA. This was not
unexpected given that the inferred intermediate (enolpyruvyl-
diphospho-5ʹ-guanosine (EPPG)) is expected to be unstable22
(Fig. 2a).
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To understand the molecular basis of PEP recognition by Mtb-
FbiD, we crystallized the protein and solved the structure by
selenium single-wavelength anomalous diffraction (Se-SAD), and
then used this selenomethionine-substituted structure to obtain
the native FbiD structure by molecular replacement. The latter
was then reﬁned at 1.99 Å resolution (R/Rfree= 0.19/0.22)
(Table 1). As expected, Mtb-FbiD adopts the same MobA-like
nucleoside triphosphate transferase family protein fold as CofC: a
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Fig. 1 The currently accepted bacterial F420 biosynthesis pathway. The pathway is composed of two branches. In the ﬁrst branch tyrosine is condensed with
the ﬂavin biosynthesis intermediate 5-amino-6-ribitylamino-2,4-(1H,3H)-pyrimidinedione by FbiC/CofGH to produce the riboﬂavin level chromophore Fo.
In the second branch, L-lactic acid is phosphorylated in a guanosine-5ʹ-triphosphate (GTP)-dependent manner by the hypothetical L-lactate kinase CofB to
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central 7-stranded β-sheet (six parallel strands and one
antiparallel), with α-helices packed on either side (Fig. 3a).
However, Mtb-FbiD lacks the protruding hairpin that is
important for dimer formation in CofC32. Superposition of CofC
from Methanosarcina mazei (PDB code 2I5E) onto Mtb-FbiD
gives a root mean square difference of 1.85 Å over 181 Cα atoms,
with 25.4% sequence identity, establishing clear structural
homology (Fig. 3c).
We also soaked PEP into pre-formed FbiD crystals to obtain an
FbiD-PEP complex (2.18 Å resolution, R/Rfree= 0.22/0.26). FbiD
has a cone-shaped binding cleft with a groove running across the
base of the cone, formed by the C-terminal end of the central β-
sheet (Fig. 3a). PEP binds in the cleft with its phosphate group
anchored through two Mg2+ ions to three acidic side chains
(D116, D188, and D190) (Fig. 3b). This three-aspartate motif is
conserved amongst FbiD homologs as shown by a multiple
sequence alignment (Supplementary Fig. 1). The PEP carboxylate
group is hydrogen bonded to the hydroxyl group of S166 and the
main chain NH groups of T148 and G163. All PEP binding
residues are conserved in the CofC protein of M. mazei (PDB
code 2I5E) (Supplementary Fig. 1), consistent with the enzymatic
assays that showed PEP is the substrate for archaeal CofC, as well
as FbiD. The reason that FbiD/CofC is active with PEP rather
than 2-PL is most likely a consequence of the different
stereochemistry of 2-PL (compared with the planar geometry of
PEP) preventing a necessary structural rearrangement, or the
binding of GTP, which would be required to attain a productive
transition state, as suggested for PEP carboxykinase33. In the
GTP-bound structure of E. coli MobA34 (PDB code 1FRW), GTP
binds in a characteristic surface groove, providing a structural
framework for substrate binding and catalysis. In our enzyme
assays, neither FbiD nor CofC showed activity in the absence of
FbiA. Moreover, we did not observe GTP binding in either our
co-crystallization or differential scanning ﬂuorimetry experi-
ments. We speculate that the GTP binding site is not formed until
FbiD/CofC interacts with FbiA/CofD, enabling catalysis to
proceed through to formation of dehydro-F420-0. This may
provide an advantage by producing EPPG/EPPA only when both
proteins are available, thereby overcoming the issue of inter-
mediate instability.
The C-terminal domain of FbiB reduces dehydro-F420-0 to
F420-0. Dehydro-F420-0 would yield F420-0 upon reduction of the
terminal methylene double bond. However, no masses corre-
sponding to F420-0 were identiﬁed in any of the liquid
chromatography-MS (LC-MS) traces from the FbiD:FbiA-cou-
pled assays, suggesting that an enzyme other than FbiD or FbiA
catalyzes dehydro-F420-0 reduction. We have previously shown
that full-length FbiB consists of two domains: an N-terminal
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domain that is homologous to the archaeal γ-glutamyl ligase
CofE21,35, and a C-terminal domain of the NTR fold36 that binds
to FMN and has no known function, but is essential for extending
the poly-γ-glutamate tail20.
We tested whether FbiB could use dehydro-F420-0 as a
substrate with a three enzyme assay in which FbiB and
L-glutamate were added to the FbiD:FbiA-coupled assay. Mtb-
FbiB was observed to catalyze the addition of L-glutamate
residues to dehydro-F420-0, forming dehydro-F420 species with
one ([M+H]+, m/z of 643.40) and two ([M+H]+, m/z of
772.40) glutamate residues (Supplementary Fig. 2). We then
tested the hypothesis that the orphan function of the FMN-
binding C-terminal domain could in fact be a dehydro-F420-0
reductase. We used a four-enzyme in vitro assay where E. coli
NAD(P)H:ﬂavin oxidoreductase37 (Fre), FMN, NADH, and 10
mM dithiothreitol (to maintain reducing conditions and
generate reduced FMNH2) were added to the FbiD:FbiA:FbiB
assay and the reaction was performed in anaerobic conditions
(to prevent reaction of FMNH2 with oxygen). We found that
F420-1, that is, the fully reduced and mature glutamylated
cofactor, was produced, but only in the presence of both FbiB
and Fre/FMNH2 (Fig. 4a). Thus, dehydro-F420-0 is a bona ﬁde
metabolic intermediate that can be converted to mature F420 by
FbiB in an FMNH2-dependent fashion. These results demon-
strate that bacterial FbiB is a bifunctional enzyme, functioning
as a dehydro-F420-0 reductase and as a γ-glutamyl ligase
(Fig. 4b).
When the previously published crystal structures of Mtb-FbiB
are analyzed in the context of these results, the molecular basis for
this activity becomes clear. Crystal structures of the Mtb-FbiB C-
terminal domain with F420 bound (PDB ID: 4XOQ) and FMN
bound (PBD ID: 4XOO) have been solved20, and when these are
overlaid it is apparent that the FMN molecule is ideally situated to
transfer a hydride to the terminal methylene of dehydro-F420-0
(assuming dehydro-F420-0 binds in a similar fashion to F420).
Interestingly, the phospholactyl group of F420 appears to be
disordered in these crystal structures, suggesting it may adopt
multiple conformations. To test this, we docked dehydro-F420-0
into the FMNH2-bound structure and performed an energy
minimization using the OPLS3e forceﬁeld to allow them to attain
a low-energy conformation. This forceﬁeld was chosen based on
its improved torsional parameters for small molecules and more
accurate descriptions of the potential energy surfaces of ligands,
allowing for improved docking poses over other forceﬁelds38. The
results show that in this ternary complex the two molecules can
adopt ideal positions and orientations for the reduction of
dehydro-F420-0 (Fig. 4c). The methylene group of dehydro-F420-0
is accommodated by a small hydrophobic pocket mostly
comprised of P289 and M372 allowing it to be positioned above
the N5 atom of FMNH2, in a plausible Michaelis complex for
hydride transfer (Fig. 4c). We therefore suggest that the
phosphoenolpyruvyl (analogous to the phospholactyl) group of
dehydro-F420-0 most likely samples conformations within this
pocket where it can be reduced.
Interestingly, the γ-glutamyl ligase CofE from archaea is a
single domain enzyme; there is no homology to the C-terminal
NTR-fold domain of FbiB. In an analogous situation, Fo synthesis
is performed by two single domain enzymes in archaea, CofH,
and CofG2, whereas in bacteria this reaction is catalyzed by a two-
domain protein, FbiC (with N- and C-terminal domains
homologous to CofH and CofG, respectively). Previous analysis
Table 1 Data collection, processing, and reﬁnement
statistics
SeMet-FbiDa Apo-FbiDa (PDB
6BWG)
FbiD-PEPa (PDB
6BWH)
Data collection
Space group C2221 C2221 C2221
Cell dimensions
a, b, c (Å) 66.56, 110.79,
167.69
66.54, 109.05,
166.49
66.17, 110.44,
165.91
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (Å) 47.17–2.33
(2.41–2.33)
46.92–1.99
(2.04–1.99)
46.84–2.18
(2.25–2.18)
Rmerge 0.13 (0.37) 0.354 (2.71) 0.213 (2.93)
I /σI 21.3 (8.1) 8.8 (1.2) 14.5 (1.0)
CC1/2 0.995 (0.97) 0.994 (0.321) 0.998 (0.376)
Completeness (%) 99.91 (99.3) 99.85 (96.9) 100.0 (99.7)
Redundancy 14.6 (14.2) 14.8 (13.5) 14.7 (13.2)
Reﬁnement
Resolution (Å) 83.25–1.99 82.95–2.18
No. reﬂections 621278 (38169) 471504 (35875)
Rwork/Rfree 19.1/22.8 22.8/26.2
No. atoms
Protein 4969 4643
Ligand/ion – 36
Water 544 180
B-factors
Protein 11.98 24.12
PEP (n= 3) – 48.78
Mg2+ (n= 6) – 44.33
Water 33.18 48.46
R.m.s. deviations
Bond lengths (Å) 0.011 0.01
Bond angles (°) 1.416 1.383
Values within parentheses are for highest-resolution shell
aNumber of crystals= 1
D116
D190 D188
K17
L92
G163 S166
T148
–5.0 5.0
a b c 
Fig. 3 Crystal structure of Mtb-FbiD. a Electrostatic surface representation of the Mtb-FbiD structure in complex with phosphoenolpyruvate (PEP), shown
as a ball-and-stick model. b The phosphate group of PEP binds to three aspartic acid side chains through two Mg2+ ions (shown in cyan). PEP is shown in
2Fo− Fc omit density contoured at 2.0σ, and drawn as ball-and-stick model. Water molecules are shown as red spheres and hydrogen bond interactions are
outlined as dashed lines. c Superposition of Mtb-FbiD (wheat ribbon) and Methanocaldococcus jannaschii (Mj-CofC) (green ribbon), indicating 1.85 Å root
mean square difference (rmsd) over 181 superimposed Cα. PEP is shown as a ball-and-stick model
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of archaeal genomes revealed that cofH and cofG are closely
associated in genomic context39. We therefore investigated the
genomic context of archaeal cofE genes to investigate whether
genes with homology to the C-terminal NTR domain of FbiB
were located nearby. From over 1000 archaeal genomes, we only
detected 16 open reading frames (ORFs) in the neighboring
context of cofE that could encode proteins with an NTR fold,
although none of these shared substantial (>34% sequence
identity) homology and all lacked the key F420 binding residues
observed in FbiB. There was one interesting exception: the
unusual archaea Lokiarchaeum sp.40 are unique among all
sequenced archaea in that they alone encode an FbiB-like
γ-glutamyl ligase:NTR fusion protein.
Expression of fbiABCD is sufﬁcient to produce F420 in
Escherichia coli. Cofactor F420 is only produced by certain bac-
terial species; the majority of bacteria, including E. coli, lack the
genes required for F420 biosynthesis. Our in vitro assay results
suggest that 2-PL and, by extension, the hypothesized L-lactate
kinase CofB are not required for heterologous production of F420
in a non-native organism. To test our hypothesis, we generated a
plasmid expressing the M. smegmatis F420 biosynthesis genes
fbiB/C/D along with the fbiA homolog cofD from M. mazei19,
which was substituted as Ms-FbiA was found to express poorly in
E. coli.
We generated two versions of a plasmid-encoded recombinant
F420 biosynthetic operon, both of which encode codon-optimized
genes for expression in E. coli: one encodes the native enzymes
(pF420), and the second encodes C-terminal FLAG-tagged versions
of the enzymes to allow their detection in a western blot (pF420-
FLAG) (Fig. 5a). Plasmids were designed to allow induction of F420
biosynthesis in the presence of anhydrotetracycline. A Western blot
using anti-FLAG antibodies was used to detect whether the proteins
were expressed in soluble form in E. coli, and conﬁrmed that all
were expressed to varying degrees (Supplementary Fig. 3). We then
tested, using HPLC with ﬂuorescence detection, whether F420 was
heterologously produced in the cell lysate of our recombinant E. coli
strain expressing this operon. As shown in Fig. 5b, E. coli expressing
both the FLAG-tagged and untagged plasmids produced traces
consistent with mature, poly-glutamylated F420, although they
differed slightly to the M. smegmatis-produced F420 standard in
terms of the distribution of poly-γ-glutamate tail lengths. We also
observed some accumulation of Fo (Supplementary Fig. 4), an
intermediate formed by FbiC, which is also observed when F420 is
produced in M. smegmatis41.
To conﬁrm that this was indeed mature F420, and not dehydro-
F420 species, we puriﬁed the compound from E. coli lysate and
performed high-resolution tandem MS (MS/MS) analysis. Mass
fragmentation did indeed show that the compound was reduced, and
not dehydro-F420 (Fig. 5d). No dehydro-F420 species were detected.
The yield of puriﬁed F420 was ~27 nmol L−1 of culture, which is
comparable to physiological levels of several F420-producing species42.
Ultraviolet–visible (UV–Vis) and ﬂuorescence spectra of the puriﬁed
F420 matched literature values (Supplementary Fig. 5)4,5. Finally, we
conﬁrmed that the puriﬁed cofactor was functional by measuring
enzyme kinetic parameters with F420-dependent glucose-6-phosphate
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dehydrogenase (FGD) from M. smegmatis (Fig. 5c). The apparent
Michaelis constant was within error of that observed with FGD and
F420 produced from M. smegmatis, while the kcat was approximately
half that of the M. smegmatis F420 (Fig. 5c), which could result from
slight differences in the distribution of tail lengths, as previously
reported (Supplementary Table 2)43. These results conﬁrm that the
heterologous production of F420 was achieved with a biosynthetic
pathway containing only CofD (a homolog of FbiA)/FbiB/FbiC/FbiD.
Having demonstrated that our recombinant E. coli strain could
produce mature F420 that was functional ex vivo, we tested whether
co-expression of F420-dependent enzymes could facilitate F420-
dependent transformations in vivo. We have previously shown that
F420H2 can decolorize malachite green nonenzymatically, and that
several F420-dependent reductases accelerate this reaction44. As
summarized in Supplementary Table 3, E. coli were unable to
decolorize malachite green without induction of F420 biosynthesis.
When the cells additionally expressed FGD and the F420-dependent
oxidoreductase MSMEG_2027, malachite green decolorization was
signiﬁcantly increased (p < 0.001, Student’s paired t test, two-sided).
These results demonstrate that incorporation of the F420 biosyn-
thetic pathway into E. coli allows F420-dependent enzymes to
function in vivo upon heterologous expression.
Discussion
It has become widely accepted within the ﬁeld that one of the
essential initial steps in F420 biosynthesis involves a hypothetical
L-lactate kinase that produces 2-PL, which is subsequently
incorporated into F420 through the activities of CofC and CofD.
However, neither bioinformatics nor genetic knockout studies
have identiﬁed plausible candidate genes for a L-lactate
kinase2,18,23. Furthermore, 2-PL has been shown to inhibit several
enzymes involved in central metabolism28–30. In terms of path-
way ﬂux, this makes 2-PL an unusual starting point for bio-
synthesis of an abundant metabolite such as F420, which can
exceed 1 μM in some species42. The results presented in this
paper unequivocally demonstrate that PEP, rather than 2-PL, is
the authentic starting metabolite in bacteria. These results
reconcile the previously problematic assumptions that are
required to include 2-PL within the biosynthetic pathway and
establish a revised pathway (Fig. 6) that is directly linked to
central carbon metabolism (via PEP) through the glycolysis and
gluconeogenesis pathways.
Our observation that CofC accepts PEP (and not 2-PL) in vitro,
appear to contradict previous studies in which Mj-CofC was
reported to use 2-PL as substrate19,35. However, this discrepancy
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is most likely due to the supplementation of the coupled CofC/
CofD reaction in these studies with pyruvate kinase and 2 mM
PEP, a strategy that was used to overcome apparent product
inhibition by GMP19,35. Regardless, we cannot explain how a
pathway starting from PEP can produce mature (i.e., not
dehydro-F420) F420 in archaea given that their equivalent of FbiB
(CofE) lacks the C-terminal domain dehydro-F420-0 reductase
domain seen in FbiB. One possibility is that an unknown
dehydro-F420-0 reductase exists elsewhere in the genome (remote
from CofE). Further studies are required to resolve this step in
archaeal F420 biosynthesis.
The discovery of dehydro-F420-0 as the product of FbiD:FbiA
activity in mycobacteria indicated that another enzyme must be
required to reduce dehydro-F420-0 and produce F420-0. This
allowed us to deﬁne the function of the orphan C-terminal
domain of mycobacterial FbiB20. The N-terminal domain is
homologous with the archaeal γ-glutamyl ligase CofE35, but is
only capable of catalyzing glutamylation of F420-120. The
C-terminal domain, which binds both F420 and FMN, is essential
for extending the poly-γ-glutamate tail of F420-020, but we could
not explain the possible function of the FMN cofactor. Here, we
show that FbiB can catalyze both poly-glutamylation and
reduction of dehydro-F420-0, via the activities of the N- and
C-terminal domains, respectively.
The increasing recognition of the importance of F420 in a
variety of biotechnological, medical, and ecological contexts
underlines the need for making the compound more widely
accessible to researchers; however, our inability to produce F420
recombinantly in common laboratory organisms has been a
major barrier to wider study. Here, we conﬁrm the results of our
in vitro experiments by showing that recombinant expression of
the four characterized F420 biosynthesis genes allows production
of F420 in E. coli. These ﬁndings should now facilitate the use of
F420 in a variety of processes with recombinant organisms, such as
biocatalysis using a bio-orthogonal cofactor, directed evolution of
F420-dependent enzymes, recombinant production of antibiotics
for which F420 is a required cofactor, and metabolic engineering.
Methods
Bacterial strains and growth conditions. Protein expression utilized either M.
smegmatis mc2451745, E. coli BL21(DE3), or LOBSTR-BL21(DE3)46 cells. For
growth of M. smegmatis, media were supplemented with 0.05% (v/v) Tween-80.
Mycobacterium smegmatis cells were grown in ZYM-505247 or modiﬁed auto-
induction media Terriﬁc Broth (TB) 2.0 (2.0% tryptone, 0.5% yeast extract,
0.5% NaCl, 22 mM KH2PO4, 42 mM Na2HPO4, 0.6% glycerol, 0.05% glucose,
0.2% lactose)48. For selenomethionine labeling, cells were grown in PASM-
5052 media47. Escherichia coli expressions were conducted in either the
above-modiﬁed auto-induction media or TB medium modiﬁed for auto-
induction of protein expression (1.2% tryptone, 2.4% yeast extract, 72 mM
K2HPO4, 17 mM KH2PO4, 2 mM MgSO4, 0.8% glycerol, 0.015% glucose, 0.5%
lactose, 0.375% aspartic acid), grown for 4 h at 37 °C followed by overnight
incubation at 18 °C.
Protein expression and puriﬁcation. Mtb-FbiD: The ORF encoding FbiD
(Rv2983) was obtained by PCR from M. tuberculosis H37Rv genomic DNA
(Supplementary Table 1). The pYUBDuet-fbiABD co-expression construct was
then prepared by cloning fbiD into pYUBDuet41 using BamHI and HindIII
restriction sites, followed by cloning the fbiAB operon using NdeI and PacI
restriction sites. This construct expresses FbiD with an N-terminal His6-tag,
whereas the FbiA and FbiB proteins are expressed without any tags.
The pYUBDuet-fbiABD vector was transformed into M. smegmatis
mc24517 strain45 for expression. The cells were grown in a fermenter (BioFlo®415,
New Brunswick Scientiﬁc) for 4 days before harvesting. The cells were lysed in
20 mM HEPES, pH 7.5, 150 mM NaCl, 20 mM imidazole, and 1 mM β-
mercaptoethanol using a cell disruptor (Microﬂuidizer M-110P) in the presence of
Complete protease inhibitor mixture mini EDTA-free tablets (Roche Applied
Science). The lysate was centrifuged at 20,000 × g to separate the insoluble material.
Recombinant FbiD was separated from other proteins by immobilized metal
afﬁnity chromatography on a HisTrap FF 5-mL Ni-NTA column (GE Healthcare),
eluted with imidazole, and further puriﬁed by size-exclusion chromatography
(SEC) on a Superdex 75 10/300 column (GE Healthcare) pre-equilibrated in
20 mM HEPES, pH 7.5, 150 mM NaCl, and 1 mM β-mercaptoethanol.
Mtb-FbiA: The ORF encoding M. tuberculosis FbiA was commercially
synthesized and cloned into pRSET-A (Invitrogen). The pYUB28b-fbiA
construct used for expression in M. smegmatis mc24517 was prepared by
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subcloning fbiA into pYUB28b41 using an NdeI site introduced by overhang
PCR utilizing the HindIII restriction site present on both vectors ampliﬁed
with the T7 reverse primer (Supplementary Table 1). The resulting pYUB28b-
fbiA construct expresses FbiA with an N-terminal His6-tag. The protein was
expressed in M. smegmatis mc24517 in ZYM-5052 media auto-induction
media47,49 in a fermenter (BioFlo®415, New Brunswick Scientiﬁc) for 4 days.
The protein was then puriﬁed using Ni-NTA and SEC steps, as described
above, in 20 mM HEPES, pH 7.5, 200 mM NaCl, 5% glycerol, and 1 mM
β-mercaptoethanol.
Mj-CofC: The ORF encoding Methanocaldococcus jannaschii CofC (MJ0887)25
was synthesized (GenScript) and cloned into pYUB28b vector41 using NdeI and
HindIII restriction sites. The protein was expressed in E. coli in TB auto-induction
media and puriﬁed using Ni-NTA and SEC steps, as described above, in 20 mM
HEPES, pH 7.5, 200 mM NaCl, 5% glycerol, and 1 mM β-mercaptoethanol.
Ec-Fre: The E. coli ﬂavin reductase37 was cloned into pProEX-HTb using KasI
and HindIII restriction sites (Supplementary Table 1). Protein expression and
puriﬁcation was performed similar to Mj-CofC.
Ms-FbiD: The ORF encoding M. smegmatis FbiD (MSMEG_2392) was
synthesized (Integrated DNA Technologies) and cloned into pETMCSIII by
Gibson Assembly as outlined previously48. The protein was expressed overnight ay
30 °C in auto-induction media and puriﬁed similarly to Mj-CofC.
Construction of synthetic F420 biosynthesis operon. Ribosome binding sites
were individually optimized for each of the codon-optimized F420 biosynthesis
genes using the Ribosome Binding Site Calculator server39,50. Multiple operon
designs were analyzed using the server’s operon calculator and modiﬁed to
remove unwanted translation products and RNA instability elements while
maintaining predicted translation initiation rates for all coding sequences
within an order of magnitude. The ﬁnal design placed the operon under the
control of the tetracycline-inducible promoter BBa_R0040 and the artiﬁcial
terminator BBa_B1006. For subsequent assembly the operon was ﬂanked by
BioBrick preﬁx and sufﬁx sequences. The operon was synthesized by GenScript
and cloned into pSB1C3 containing the constitutive tetracycline repressor
cassette BBa_K145201 using the standard BioBrick assembly protocol with
EcoRI and XbaI/SpeI restriction enzymes51. This construct, hereafter referred
to as pF420, enables production of F420 to be induced by the addition of
anhydrotetracycline. For Western blot analysis as second version of the operon
with single C-terminal FLAG tags on all four genes was likewise synthesized.
To test for in vivo F420-depended reductase/oxidase activity, the ORF of M.
smegmatis FGD (MSMEG_0777) was codon optimized and commercially
synthesized by GenScript and cloned into multiple cloning site 1 of pCOLADuet-1
(Novagen) using NcoI and HindIII sites. Subsequently MSMEG_2027 was
subcloned from pETMCSIII-MSMEG_202748 into multiple cloning site 2 using
NdeI and KpnI to give pFGD_2027.
Mtb-FbiD crystallization and structure determination. Apo-FbiD (20 mgmL−1
in 20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM β-mercaptoethanol) was crys-
tallized using the sitting drop vapor diffusion method in 30% polyethylene glycol
1500, 3% MPD (2-methyl-2,4-pentanediol), 0.2 M MgSO4, and 0.1 M sodium
acetate, pH 5.0. For experimental phasing, selenomethionine-substituted FbiD
crystals were grown using protein produced in M. smegmatis host cells49. Se-SAD
anomalous diffraction data sets were collected at the Australian Synchrotron. Data
collection statistics are summarized in Table 1. Crystals of Mtb-FbiD in complex
with PEP were obtained by soaking pre-formed apo crystals in precipitant solutions
containing 10 mM PEP for 30 min.
All data sets were indexed and processed using XDS52, and scaled with
AIMLESS53 from the CCP4 program suite54. The structure was solved using
the SAD protocol of Auto-Rickshaw55, the EMBL-Hamburg automated crystal
structure determination platform. Based on an initial analysis of the data, the
maximum resolution for substructure determination and initial phase
calculation was set to 2.83 Å. All three of the expected heavy atoms were found
using the program SHELXD56. The initial phases were improved using density
modiﬁcation and phase extension to 2.33 Å resolution using the program
RESOLVE57. Cycles of automatic model building by ARP/wARP58 and phenix.
autobuild59 resulted in a protein model that was completed manually using
COOT60. Water molecules were identiﬁed by their spherical electron density
and appropriate hydrogen bond geometry with the surrounding structure.
Following each round of manual model building, the model was reﬁned using
REFMAC561, against the data to 1.99 Å resolution. The PDB_redo program62
was used in the ﬁnal stages of reﬁnement. Full reﬁnement statistics are shown
in Table 1.
The structure of Mtb-FbiD in complex with PEP was solved by molecular
replacement using PHASER63 with the apo-FbiD structure as a search model.
The structure was reﬁned by cycles of manual building using COOT60 and
reﬁnement using REFMAC561, against the data to 2.18 Å resolution. Full
reﬁnement statistics are shown in Table 1. The Ramachandran statistics
analyzed using MolProbity64 are 99.18% favored, 0.82% allowed, and 0.0%
outliers for apo-FbiD and 99.02% favored, 0.98% allowed, and 0.0% outliers for
PEP-FbiD.
Multiple sequence alignments were performed using Expresso from the
T-Coffee suite65 with the structure of Mtb-FbiD. Figures were prepared using
the ESPript 3.0 web server66.
HPLC assays. FbiD/CofC-FbiA-coupled activity was monitored in a reaction
mixture containing 100 mM HEPES, pH 7.5, 2 mM GTP, 0.1 mM Fo, 5 mMMgCl2,
1 mM 2-PL or PEP, 1 μM FbiD, and 5 μM FbiA. The reactions were incubated at
37 °C and stopped using 20 mM EDTA at various time points. Separation of F420
species was performed on an Agilent HP 1100 HPLC system equipped with
photodiode array and ﬂuorescence detectors (Agilent Technologies). Samples were
kept at 4 °C, and the injection volume was 20 μL. Samples were separated on a
Phenomenex Luna C18 column (150 × 3 mm2, 5 μm) with a 0.2 μm in-line ﬁlter
that was maintained at 30 °C. The mobile phase consisted of 100% methanol (A)
and 25 mM sodium acetate buffer, pH 6.0 (B), with a gradient elution at a ﬂow rate
of 0.5 mL min−1 and a run time of 30 min. The gradient proﬁle was performed as
follows: 0–25 min 95–80% B, 25–26 min 80% B, 26–27 min 95% B, 27–30 min 95%
B, and a post-run of 2 min. The wavelengths used for photodiode array were 280
and 420 nm (bandwidth 20 nm) using a reference of 550 nm (bandwidth 50 nm).
The wavelengths used for the ﬂuorescence detector were 420 nm (excitation) and
480 nm (emission).
LC-MS characterization of dehydro-F420 species. Enzymatic reactions were set
up as described above. Ten microliters aliquots were injected onto a C18 trap
cartridge (LC Packings, Amsterdam, The Netherlands) for desalting prior to
chromatographic separation on a 0.3 × 100 mm2 3.5 μm Zorbax 300SB C18
Stablebond column (Agilent Technologies, Santa Clara, CA, USA) using the
following gradient at 6 μL min−1: 0–3 min 10% B, 24 min 50% B, 26 min 97% B,
29 min 97% B, 30.5 min 10% B, 35 min 10% B, where A was 0.1% formic acid in
water and B was 0.1% formic acid in acetonitrile. The column eluate was
ionized in the electrospray source of a QSTAR-XL Quadrupole Time-of-Flight
mass spectrometer (Applied Biosystems, Foster City, CA, USA). For IDA
(Information Dependent Analysis) analyses, a TOF-MS scan from 330–1000
m/z was performed, followed by three rounds of MS/MS on the most intense
singly or doubly charged precursors in each cycle. For targeted work, deﬁned
Product Ion Scans were created to isolate and fragment speciﬁc ions of interest
with various collision energies (10–60 kV). Both positive and negative modes
of ionization were used as appropriate.
MS/MS conﬁrmation of reduction of dehydro-F420 species. To conﬁrm the
reduction of the PEP moiety in vitro assays were prepared in 50 mM HEPES
pH 7.5, 100 mM KCl, 5 mM MgCl2, 2 mM GTP, 0.1 mM Fo, 1 mM PEP, 5 μM
Mtb-FbiA, 6.5 μM Msg-FbiD, 10 mM DTT, 20 μM FMN, 0.2 mM NADH, 0.1
μM Ec-Fre, 2 μM Mtb-FbiB and 1 mM L-glutamate. To minimize futile oxi-
dation of FMNH2 by oxygen the reaction mixture was repeatedly evacuated
and purged with nitrogen and maintained under a nitrogen atmosphere.
Samples were incubated at ambient temperature for up to 36 h and stopped by
addition of 20 mM EDTA. Samples were desalted using Bond Elut C18 tips
(Agilent Technologies) and eluted in 0.1% formic acid in acetonitrile.
Samples were injected onto a Q Exactive Plus (Thermo Fisher Scientiﬁc) at
100 μLmin−1 with isocratic 50% B, where A was 10 mM ammonium acetate,
pH 6.0, and B was 0.02% ammonia in methanol. Scans from 150–2250m/z
were performed and data-dependent MS/MS on targeted metabolites was done
in both positive and negative modes.
Docking dehydro-F420-0 into FbiB C-terminal domain. Structures of FbiB
C-terminal domain bound with F420-0 (4XOQ) and FMN (4XOO) were aligned
in PyMOL and the ligands removed from the structures. Chemical dictionaries
of dehydro-F420-0 and FMNH2 were prepared with AceDRG67 and built into
the same molecule with COOT60 using the two density maps as appropriate.
Dehydro-F420-0 was then reparametrized using the OPLS3e forceﬁeld38 in
Maestro (Schrödinger Release 2018-4: Maestro, Schrödinger, LLC, New York,
NY, 2018). The energy was minimized using the energy minimization function
of Desmond (Schrödinger Release 2018-4: Desmond Molecular Dynamics
System, D. E. Shaw Research, New York, NY, 2018; Maestro-Desmond Inter-
operability Tools, Schrödinger, New York, NY, 2018).
Production of F420 in Escherichia coli. The pF420 vector was transformed into E.
coli BL21(DE3) for expression. Cells were cultivated in M9 minimal media
supplemented with chloramphenicol (25 µg mL−1) and tyrosine (18 μg mL−1)
in 1 L shake ﬂasks with 500 mL working volume at 28 °C. At an optical density
(OD) of 0.60, 200 ng mL−1 of tetracycline was added to induce the expression
of F420 biosynthesis pathway. After induction, cells were cultivated for at least
16 h. To test the expression of the F420 biosynthetic genes, cell pellets were
lysed by resuspending to OD of 0.8 in buffer containing BugBuster (Novagen).
Following centrifugation at 16,000 × g, proteins were resolved on a gel (BoltTM
4–12% Bis-Tris Plus, Invitrogen) for 1 h and visualized using Coomassie
Brilliant Blue. For immunoblotting, proteins were transferred to a membrane
(iBlot® 2 NC Regular Stacks, Invitrogen) using iBlot Invitrogen (25 V, 6 min).
After staining and de-staining, the membrane was blocked with 3% skim milk
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solution and blotted with anti-FLAG antibodies conjugated with HRP
(DYKDDDDK Tag Monoclonal Antibody, Thermo Fisher Scientiﬁc, MA1-
91878-HRP, ×1000 dilution).
For detection of F420 in E. coli lysate by HPLC-FLD, cells were grown overnight
in media containing 2.0% tryptone, 0.5% yeast extract, 0.5% NaCl, 22 mM
KH2PO4, 42 mM Na2HPO4, 100 ng mL−1 anhydrotetracycline, and 34 μg mL−1
chloramphenicol at 30 °C. Cells from 500 μL of culture were pelleted by
centrifugation at 16,000 × g. Cells were re-suspended in 500μL of 50 mM Na2HPO4,
pH 7.0, and lysed by boiling at 95 °C for 10 min. Cell debris was pelleted by
centrifugation at 16,000 × g and ﬁltered through a 0.22 μm PVDF ﬁlter. Analysis
was conducted as described previously2. pSB1C3 containing only BBa_K145201
was used as a control.
Puriﬁcation and analysis of Escherichia coli-produced F420. For F420 extraction,
1 L of cell culture was centrifuged at 5000 × g for 15 min. The cell pellet was re-
suspended in 30 mL of 75% ethanol and boiled at 90 °C in a water bath for 6 min
for cell lysis. The cell extract was again centrifuged at 5000 × g for 15 min to
remove cell debris and the supernatant was lyophilized. The lyophilized cell
extract was re-dissolved in 10 mL milli Q water centrifuged at 5000 × g for 15
min and the supernatant passed through 0.45 μm syringe ﬁlter (Millex-HV). The
ﬁltered cell extract was puriﬁed for F420 using a 5 mL HiTrap QFF column
(GE Healthcare) as previously described41. The puriﬁed F420 solution was further
desalted by passing it through C18 extract column (6 mL, HyperSep C18 Car-
tridges, Thermo Fisher Scientiﬁc). The C18 extract column was ﬁrst equilibrated
by passing through 10 mL of 100% methanol and 10 mL of milli Q. Afterwards,
the F420 solution was passed through the C18 extract column, and F420 was
eluted in 2 mL fraction of 20% methanol. The puriﬁed F420 solution was further
concentrated in GeneVac RapidVap and re-dissolved in 500 μL of milli Q for
further analysis and assays. To detect Fo accumulation in the media, it was
ﬁltered through a 0.45 μm syringe ﬁlter and puriﬁed directly on the C18 extract
column as above.
UV and ﬂuorescence spectra were collected on a Varian Cary 60 and a Varian
Cary Eclipse, respectively, in a 10 mm QS quartz cell (Hellma Analytics). Samples
were buffered to pH 7.5 with 50 mM HEPES and scanned from 250 to 600 nm. For
ﬂuorescence, the excitation wavelength was 420 nm and the emission scanned from
435 to 600 nm.
Activity assays with M. smegmatis and E. coli-derived F420 were conducted with
M. smegmatis FGD expressed and puriﬁed as described previously15. Assays were
performed in 50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 50 nM FGD, 5 μM F420, and
0–1000 μM glucose-6-phosphate using a SpectraMAX e2 plate reader. Activity was
measured by following loss of F420 ﬂuorescence at 470 nm. Apparent kcat and Km
values were calculated using the GraphPad Prism 7.04 (GraphPad Software, La
Jolla, CA, USA).
For malachite green reduction assays, cells were grown in 50 mL Falcon
tubes containing 30 mL M9 minimal media, and supplemented with
appropriate antibiotics at 28 °C. Cells were induced at OD600 of 0.6 by the
addition of 200 ng μL−1 tetracycline and 0.2 mM isopropyl β-D-1-
thiogalactopyranoside. Cells were grown for an additional 6 h before adding
malachite green to an initial OD615 of 0.26. Cultures were covered in foil and
grown in the dark to prevent spontaneous decolorization. After overnight
incubation, OD at 615 nm was measured with assays conducted in triplicate.
Statistical analysis was performed using GraphPad Prism 7.04 (GraphPad
Software, La Jolla, CA, USA).
2-PL synthesis. In the absence of a commercial source, 2-PL was chemically
synthesized by a slight modiﬁcation of the method of Ballou and Fischer68.
Brieﬂy, benzyl lactate was condensed with chlorodiphenyl phosphate in pyr-
idine, with cooling, to give benzyldiphenylphosphoryl lactate. Hydrogenolysis
of this material in 70% aqueous tetrahydrofuran over 10% Pd-C gave phos-
pholactic acid as a colorless, viscous oil, which was characterized by proton,
carbon, and phosphorus nuclear magnetic resonance (NMR) spectroscopy, and
by MS. 1H NMR (DMSO-d6) δ 11.68 (br, 3H), 4.53 (m, 1H), 1.36 (d, J= 6.8 Hz,
3H). 13C NMR (DMSO-d6) δ 172.50 (d, JP–C= 0.05 Hz), 69.56 (d, JP–C= 0.04
Hz), 19.27 (d, JP–C= 0.04 Hz). 31P NMR (DMSO-d6) δ −1.64. APCI-MS found:
[M+H]+ = 171.1, [M−H]−= 169.1.
Fo puriﬁcation. Fo was puriﬁed from M. smegmatis culture medium over-
expressing Mtb-FbiC as described previously41.
Genomic context analysis. A non-redundant CofE dataset of 4813 sequences
was collected using the Pfam identiﬁer PF01996 and the InterPro classiﬁcations
IPR008225, IPR002847, and IPR023659. Archaeal CofE sequences were
extracted from this dataset, resulting in a set of 1060 sequences that included
representatives across 12 phyla: Crenarchaeota, Euryarchaeota, Thaumarch-
aeota, Candidatus Bathyarchaeota, Candidatus Diapherotrites, Candidatus
Heimdallarchaeota, Candidatus Korarchaeota, Candidatus Lokiarchaeota,
Candidatus Marsarchaeota, Candidatus Micrarchaeota, Candidatus
Odinarchaeota, and Candidatus Thorarchaeota. The genomic context
(10 upstream and 10 downstream genes) of each archaeal cofE was analyzed for
the presence of a neighboring PF00881 domain with homology to the C-
terminal domain of FbiB using the Enzyme Function Initiative—Genome
Neighborhood Tool69.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The coordinates and structure factors for the PEP-bound and apo structures of Rv2983
have been deposited in the Protein Data Bank under the accession codes “6BWH” and
“6BWG,” respectively. All other data are available from the corresponding authors upon
request.
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